Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
ANI Pharma Inc
(NQ:
ANIP
)
55.99
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about ANI Pharma Inc
< Previous
1
2
3
4
Next >
A Peek at ANI Pharmaceuticals's Future Earnings
November 07, 2024
Via
Benzinga
Critical Insights From ANI Pharmaceuticals Analyst Ratings: What You Need To Know
October 22, 2024
Via
Benzinga
ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential
October 11, 2024
Piper Sandler has initiated coverage on ANI Pharmaceuticals, emphasizing its strategic shift towards high-margin brand assets, particularly the successful Cortrophin Gel, which has seen substantial...
Via
Benzinga
Peeling Back The Layers: Exploring ANI Pharmaceuticals Through Analyst Insights
October 11, 2024
Via
Benzinga
In-Depth Examination Of 4 Analyst Recommendations For ANI Pharmaceuticals
September 17, 2024
Via
Benzinga
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
September 11, 2024
Via
Benzinga
Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts
April 23, 2024
Via
Benzinga
Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts
March 05, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
ANI Pharmaceuticals's Earnings Outlook
February 28, 2024
Via
Benzinga
ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
ANIP stock results show that ANI Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
June 26, 2024
Via
Benzinga
Nasdaq Records Worst Session Since April With Nvidia Plunging 7%: Dow Jones Sees Modest Gains Amid Mixed Market Close
June 25, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
June 24, 2024
Alimera Sciences stock is up on Monday as investors react to a $5.50 per share acquisition offer for ALIM from ANI Pharmaceuticals.
Via
InvestorPlace
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal
June 24, 2024
ANI Pharmaceuticals to acquire Alimera Sciences for $5.50 per share in cash, plus a contingent value right of up to $0.50 per share. The transaction is valued at $381 million and is expected to close...
Via
Benzinga
Expert Ratings for ANI Pharmaceuticals
October 19, 2023
Via
Benzinga
Analyst Expectations for ANI Pharmaceuticals's Future
September 13, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About ANI Pharmaceuticals
August 21, 2023
Via
Benzinga
ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
May 10, 2024
ANIP stock results show that ANI Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Alphabet, Dover And 2 Other Stocks Insiders Are Selling
March 11, 2024
The Nasdaq 100 closed lower by around 1.5% on Friday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Drug Maker Organon Stock Scores Relative Strength Upgrade
February 28, 2024
In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday.
Via
Investor's Business Daily
Truist Securities Maintains Buy Rating for ANI Pharmaceuticals: Here's What You Need To Know
February 16, 2024
Via
Benzinga
Why Is Generic Drug Player ANI Pharmaceuticals Stock Trading Lower Today?
November 08, 2023
ANI Pharmaceuticals Inc's (NASDAQ: ANIP) third-quarter revenues were $131.8 million, up 57.3% Y/Y, beating the
Via
Benzinga
7 A-Rated Biotech Stocks for Your August Buy List
August 17, 2023
Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge.
Via
InvestorPlace
Where ANI Pharmaceuticals Stands With Analysts
July 21, 2023
Via
Benzinga
Looking Into ANI Pharmaceuticals's Return On Capital Employed
May 23, 2023
Via
Benzinga
Why ANI Pharmaceuticals Stock Is Soaring Today
May 08, 2023
ANI Pharmaceuticals Inc's (NASDAQ: ANIP) Q1 revenues were $106.8 million, +65.6% Y/Y, beating the
Via
Benzinga
Stocks Reverse Gains Ahead Of Slew Of Inflation Data
May 08, 2023
Stocks are lower this afternoon, as investors await a deluge of inflation data amid a rally for the banking sector.
Via
Talk Markets
Why Tredegar Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
May 08, 2023
Gainers Trevena, Inc. (NASDAQ: TRVN) shares surged 170% to $1.74 after the company announced the approval of OLINVYK in China.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 08, 2023
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.